Three-Pronged attack on rare blood cancer enters human testing
NCT ID NCT07464210
Summary
This study is testing a new three-drug combination for people newly diagnosed with Waldenstrom's macroglobulinemia, a rare blood cancer. It will see if adding a new drug called nemtabrutinib to two existing drugs (bortezomib and rituximab) is safe and effective at controlling the disease. The trial will enroll about 19 adults with symptomatic disease who have not had prior treatment for this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.